Richard Denison, Ph.D., is a Senior Scientist.
Section 8(e) of the Toxic Substances Control Act (TSCA) requires any company that manufactures, imports, processes or distributes chemicals in the U.S. to notify EPA within 30 days if it obtains new information that “reasonably supports the conclusion that such substance or mixture presents a substantial risk of injury to health or the environment.” Are there Section 8(e) notices for nanomaterials? Read More
John Balbus, M.D., M.P.H., is Chief Health Scientist.
At its most recent meeting a few weeks ago, the US Technical Advisory Group (TAG) to the International Standards Organization (ISO) Technical Committee on Nanotechnologies approved a motion to have ISO develop a Technical Report based on the EDF-Dupont Nano Risk Framework (NRF). Or to put it another way in acronym-laden Washington-speak, the US TAG to the ANSI-accredited ISO TC229 approved a TR based on the EDF-DD NRF. Read More
Cal Baier-Anderson, Ph.D., is a Health Scientist.
We often think of nanotechnology as the latest product of ultra-modern science, but humans did not invent the nanoscale. We were not even the first to use materials with nanoscale features: The gecko beat us to it by several million years. Even more impressive, this little reptile has managed to use nanoscale materials apparently without experiencing any ill effects. It remains to be seen if we will be able to do this.
Read More
John Balbus, M.D., M.P.H., is Chief Health Scientist.
The history of health and environmental impacts of fuel additives is not a pretty one. From tetra-ethyl lead to methyl tert-butyl ether (MTBE), we’ve learned the hard way that what goes in the tank ends up in our bodies and the environment sooner or later. Getting a thorough understanding of the potential risks of a new fuel additive at an early stage is essential to avoid a lot of harm, suffering, and economic costs down the line.
A new study by Park et al. has assessed the potential respiratory risks of a fuel additive called Envirox (nanoparticulate cerium oxide), giving it a clean bill of health based only on in vitro tests. Is this the vision of the future of risk assessment? Should we feel safe? Read More
Cal Baier-Anderson, Ph.D., is a Health Scientist.
With conventional chemicals, experience has allowed us to articulate general criteria based on chemical properties that identify chemicals of greatest concern. For example, persistent and bioaccumulative chemicals are assigned a high priority, whereas chemicals that quickly degrade and don’t build up in blood or tissue are, as a rule, likely to be of lower priority.
Concerns about nanomaterials arise from observations that properties that emerge or are greatly enhanced at the nanoscale can alter behavior, including biological activity. These properties make such materials different from conventional forms of the same chemicals. But can a general principle that nanomaterials pose a greater concern than their conventional counterparts be supported? Read More
Scott Walsh, MBA, is a Project Manager.
As we’ve noted in this blog and elsewhere, there’s a ton of uncertainty out there about what potential risks may arise from the production, use and disposal of engineered nanomaterials. And unfortunately for companies trying to work with such materials (and the rest of us who may be exposed to them), there’s still not much guidance on how to identify, manage and mitigate potential risks.
On April 2nd and April 8th, Terry Medley and Keith Swain from DuPont and I will be leading two interactive workshops on nano risk management. Read More
